The pharmacy benefit manager Prime Therapeutics published an analysis last summer that highlights this ongoing challenge with respect to the real-world effectiveness over time of the GLP-1 drugs used to treat obesity: Most overweight or obese patients without diabetes stop treatment within the first few years
There is a strong interest in developing obesity treatments based on glucagon-like peptide-1 (GLP-1) agonists, which have proved to limit morbidity and mortality in type 2 diabetes
All gut benefits aside, Akkermansia also shines in supporting a healthy metabolism
In: The Third International Conference on the Development of Biomedical Engineering in Vietnam: BME2010, 11-14 January, 2010, Ho Chi Minh City, Vietnam
Insulin helps blood glucose enter your bodys cells for later energy use
Additionally, 49% of patients on the 30 mg dose achieved HbA1c levels below 7%, compared to only 21% in the placebo group